GlassScriptPhysician profile
Jawdat A Nikoula
NPI 1144228453
$5,868.63
in general payments reported to CMS, 2019-2025
48 companies · $736 in 2025
The $736 reported for 2025 was more than what 80% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $924 · 2020: $772 · 2021: $908 · 2022: $1,280 · 2023: $638 · 2024: $611 · 2025: $736.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,984.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,984.37 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $998.23 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Merz North America, INC. | $610.91 | 2019-2022 | |
| Abbvie INC. | $534.89 | 2019-2025 | |
| Abbott Laboratories | $511.73 | 2022-2025 | Proclaim, Freestyle Libre 3 |
| Lilly USA, LLC | $383.81 | 2019-2025 | Jardiance, Mounjaro, Zepbound |
| Takeda Pharmaceuticals U.S.A., INC. | $312.38 | 2020-2025 | Trintellix |
| Pfizer INC. | $307.54 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $258.03 | 2019-2022 | |
| Amarin Pharma, INC. | $251.67 | 2019-2022 | |
| Glaxosmithkline, LLC. | $172.43 | 2019-2023 | Shingrix, Trelegy Ellipta |
| Boehringer Ingelheim Pharmaceuticals, INC. | $111.61 | 2020-2024 | Jardiance |
| Astrazeneca Pharmaceuticals LP | $97.39 | 2020-2025 | Airsupra, Farxiga |
| Astellas Pharma US INC | $94.61 | 2020-2024 | Veozah |
| Intuitive Surgical, INC. | $92.05 | 2023 | Da Vinci Surgical System |
| Merck Sharp & Dohme LLC | $89.23 | 2019-2025 | Capvaxive, Gardasil 9 |
Show all 48 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jawdat Nikoula listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.